2016 International Congress

Wednesday, June 22, 2016

12:00pm-1:30pm

The clinical characteristics of Lewy body disease showed autonomic failures preceding motor signs

A. Miyake, T. Yamamoto, K. Ikeda, T. Furuya, M. Takashi, Y. Ito, Y. Nakazato, N. Tamura, N. Araki (Irumagun Moroyama Town, Japan)

Phenomenology and clinical assessment of movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The clinical significance of brain microbleed in Alzheimer’s disease patients with Parkinsonian signs

J.Y. Ahn, H.T. Kim (Seoul, Korea)

Cognitive disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The cognitive profile of idiopathic REM sleep behavior disorder

L. Bernier-Lalonger, F. Escudier, P.A. Bourgouin, R.B. Postuma, J. Montplaisir, J.F. Gagnon (Montreal, QC, Canada)

Parkinson's disease: Cognition  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The dopamine agonist withdrawal syndrome rating scale (DAWS-RS): Initial development of a new non-motor scale

L.S. Croll, K.M. Montgomery, C.V. Kulick, M.J. Nirenberg (New York, NY, USA)

Rating scales  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The effect of an eight-week mindfulness training intervention on emotion related brain activation in people with Parkinson’s disease

B.A. Pickut, W. Van Hecke, P. Cras, E. Kerckhofs, S. Vanneste, D. Crosiers, P. Marien, P.M. Parizel (Grand Rapids, MI, USA)

Parkinson's disease: Neuroimaging and neurophysiology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The effect of anodal transcranial direct current stimulation (tDCS) on sequential motor skill learning in persons with Parkinson’s disease

E. Kerckhofs, N. Deroost (Brussels, Belgium)

Parkinson's disease: Cognition  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The effect of dopamine on global versus specific inhibitory control in Parkinson’s disease

D. Kuebler, H. Schroll, R. Eva, A. Diepold, C. Meyer, A. Kuhn (Berlin, Germany)

Cognition and Psychiatry

12:00pm-1:30pm

The effect of dopaminergic therapy on stimulus-response learning and decision-making in Parkinson’s disease using fMRI

P.A. MacDonald, N.M. Hiebert, K.N. Seergobin, A.M. Owen (London, ON, Canada)

Parkinson's disease: Neuroimaging and neurophysiology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The effect of statin use on cognition in Parkinson’s disease

B.L. Deck, J. Rick, S.X. Xie, A. Chen-Plotkin, J.E. Duda, J.F. Morley, L.M. Chahine, N. Dahodwala, R.S. Akhtar, J.Q. Trojanowski, D. Weintraub (Philadelphia, PA, USA)

Parkinson's disease: Cognition  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

The effects of deep brain stimulation for Parkinson’s disease on cognition and perceived quality of life: Preliminary results from an Ecuadorian sample

M.B. Jurado Noboa, R. Santibañez Vásquez, J. Achi, M. Navarrete, C. Mawyin (Guayaquil, Ecuador)

Parkinson's disease: Cognition  ·  Exhibit Hall located in Hall B, Level 2